There is benefit in inhaling β2-agonist (SABA) in wheezing infants evaluated by RVRTC.
The FEF75, FEF25–75, followed by FEV0.5 showed increase after β2-agonist.
The RVRTC was the method used to assess BDR, but is not the only method available.
Wheezing infants had lower lung function and higher percentage of change post BD.